| Literature DB >> 35693813 |
Yongxin Huang1,2,3, Qinyuan Xu4, Jiang Zhang1,2,3, Yanze Yin1,2,3, Yixiao Pan1,2,3, Yuanyi Zheng4, Xiaojun Cai4, Qiang Xia1,2,3, Kang He1,2,3.
Abstract
Oxidative stress and excessive inflammatory responses are the two critical mechanisms of hepatic ischemia-reperfusion injury (HIRI) encountered in many clinical settings, including following hepatectomy and liver transplantation. Effective anti-inflammatory and anti-oxidative pharmacological interventions are urgently needed to counter HIRI. The present study showed that a biocompatible Prussian blue (PB) scavenger with reactive oxygen species (ROS) scavenging and anti-inflammatory properties might be used a promising treatment for HIRI. Following intravenous administration, PB scavenger was mainly distributed in the liver, where it showed excellent ability to alleviate apoptosis, tissue injury and organ dysfunction after HIRI. PB scavenger was found to protect liver tissue by scavenging ROS, reducing neutrophil infiltration and promoting macrophage M2 polarization. In addition, PB scavenger significantly reduced oxidative stress in primary hepatocytes, restoring cell viability under oxidative stress condition. PB scavenger effectively reduced lipopolysaccharide-stimulated inflammation in RAW 264.7 cells. These findings indicate that PB scavenger may be a potential therapeutic agent for the treatment of HIRI, providing an alternative treatment for ROS-associated and inflammatory liver diseases.Entities:
Keywords: inflammation; liver ischemia-reperfusion injury; macrophage polarization; prussian blue; reactive oxygen species
Mesh:
Substances:
Year: 2022 PMID: 35693813 PMCID: PMC9174572 DOI: 10.3389/fimmu.2022.891351
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 8.786
Figure 1Characterization and multi-enzyme-like activity of PB. (A) SEM image of PB. (B) DLS determination of hydrodynamic diameter distribution. (C) X-ray diffraction patterns. (D) Fe 2p XPS spectrum. (E) Characteristic UV-vis peak of PB by UV–vis. (F) FT-IR spectra of PB. (G) Effect of incubation in different media for 7 days on the UV–vis absorbance of PB. (H) Rate of generation of dissolved oxygen (Inset: Digital photo of O2 bubbles generated from H2O2 15 min after mixing the reagents). (I) ESR signal of DMPO/(FeSO4+ H2O2)-generated •OH. (J) ESR analysis of the •OH scavenging effect of different concentrations of PB (R2 = 0.99275). (K) Schematic representation of the mechanism by which PB scavenges ROS.
Figure 2PB scavengers significantly alleviated hepatic ischemia/reperfusion injury in mice. (A) Generation of an in vivo hepatic I/R injury model in mice. (B, C) Serum concentrations of (B) ALT and (C) AST in mice after 90 min of ischemia and 6 h of reperfusion (n = 6). (D) H&E staining of liver tissue harvested from mice administered different treatments. (E) Histological severity of hepatic IRI graded using Suzuki’s score (n = 6). (F) TUNEL staining of liver sections. (G) Quantification of hepatic apoptotic areas in TUNEL-stained liver tissue (n = 4). (H) ROS levels of fresh liver tissue from various groups of mice (n = 4). (I) MDA levels of liver sections from various groups of mice (n = 6). *P < 0.05 versus the sham group; #P < 0.05 versus the PBS + I/R group. All scale bars = 100 μm.
Figure 3PB scavengers promoted Kupffer cells polarization to M2, reduced neutrophil infiltration and protected liver against inflammatory damage after I/R. (A–C) Expression of mRNAs encoding pro-inflammatory (TNF-α, IL-1β) and anti-inflammatory (IL-10) cytokines in mouse liver (n = 6). (D, E) Serum concentration of (D) TNF-α and (E) IL-10 in mice after various treatments (n = 6). (F) MPO activity in liver sections of mice after various treatments (n = 6). (G, H) Immunofluorescence staining of liver tissue with F4/80 (green), iNOS/CD206 (red), markers of M1 and M2 macrophages, respectively, and the nucleus (blue) in various groups of mice. *P < 0.05 versus the sham group; #P < 0.05 versus the PBS + I/R group. All scale bars = 100 μm.
Figure 4Cytoprotective effect of PB scavengers against oxidative stress injury in primary hepatocytes. (A) Viability of primary hepatocytes after treating with different concentrations of PB scavengers for 24 hours (n = 5). (B) Intracellular iron levels in primary hepatocytes treated with various concentrations of PB scavengers (n = 4). (C) Effect of various concentrations of H2O2 on the viability of primary hepatocytes in the absence or presence of PB scavengers (50 μg/mL) (n = 5). (D) Fluorescence microscopy imaging of intracellular oxidative stress in primary hepatocytes after treatment with H2O2 (100 μM) for 16 h with or without PB scavengers (50 μg/mL). *P < 0.05 versus control group. ***P < 0.001 versus non-PB-protected groups. All scale bars = 100 μm.
Figure 5PB scavengers alleviated LPS-induced inflammation in RAW 264.7 cells. (A–D) Effect of PB scavengers on the expression of mRNAs encoding the proinflammatory (TNF-α, IL-1β) and anti-inflammatory (IL-10, ARG-1) cytokines in LPS activated RAW 264.7 cells (n = 5). (E, F) Secretion of TNF-α and IL-10 by LPS activated RAW 264.7 cells treated with or without PB scavengers (n = 5). (G) Flow cytometry analysis of intracellular oxidative stress in the RAW 264.7 cells after LPS activation in the absence or presence of PB scavengers (50 μg/mL). (H) Quantitative representation of the flow cytometry results in G (n = 4). *P < 0.05 versus control group; #P < 0.05 versus the LPS-activated group.
Figure 6In vivo biosafety of PB scavengers (A) H&E staining of the major organs of mice administered different treatments. (B) Hematological assays of mice 24 h after intravenous injection of PB scavengers (n = 4). All scale bars = 100 μm.
Scheme 1Schematic diagram of the mechanisms by which PB scavengers protect against hepatic ischemia reperfusion injury. Prophylactically administered, PB scavengers can alleviate hepatic ischemia reperfusion injury by scavenging ROS in primary hepatocytes, reducing neutrophil infiltration and promoting macrophage polarization to the anti-inflammatory M2 type. Figure drawn by Figuredraw (www.Figuredraw.com).